CollPlant Biotechnologies (NASDAQ:CLGN) & VectivBio (NASDAQ:VECT) Head to Head Review

CollPlant Biotechnologies (NASDAQ:CLGN) and VectivBio (NASDAQ:VECT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

21.7% of CollPlant Biotechnologies shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 9.7% of VectivBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares CollPlant Biotechnologies and VectivBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
VectivBio	N/A	N/A	N/A

Valuation and Earnings

This table compares CollPlant Biotechnologies and VectivBio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37 million	2.26	-$11.49 million	($1.45)	-0.26
VectivBio	N/A	N/A	N/A	N/A	N/A

VectivBio has lower revenue, but higher earnings than CollPlant Biotechnologies.

Analyst Recommendations

This is a summary of current recommendations and price targets for CollPlant Biotechnologies and VectivBio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1	1	1	0	2.00
VectivBio	0	0	0	0	0.00

CollPlant Biotechnologies currently has a consensus target price of $11.50, suggesting a potential upside of 2,999.73%. Given CollPlant Biotechnologies’ stronger consensus rating and higher possible upside, equities analysts plainly believe CollPlant Biotechnologies is more favorable than VectivBio.

Summary

CollPlant Biotechnologies beats VectivBio on 5 of the 9 factors compared between the two stocks.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.